Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic
Activists in the access-to-medicines movement have mobilized to combat the threat of vaccine/therapeutic apartheid during the COVID-19 pandemic.
Intellectual Property
-
Read more: Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic -
Read more: The Prospects for an IP Waiver Under the TRIPS Agreement The Prospects for an IP Waiver Under the TRIPS Agreement
Going forward, practical solutions should focus on scaling up manufacturing and supply, and improving access and affordability.
-
Read more: The Patent Trial and Appeal Board Again Survives Supreme Court Review The Patent Trial and Appeal Board Again Survives Supreme Court Review
For the generic drug and biosimilar industries, the Supreme Court’s recent decision in United States v. Arthrex, Inc. comes as a relief.
-
Read more: US Support for a WTO Waiver of COVID-19 Intellectual Property – What Does it Mean? US Support for a WTO Waiver of COVID-19 Intellectual Property – What Does it Mean?
An explanation of the WTO waiver of COVID-19 intellectual property, what the U.S. declaration of support means, and likely effects of the waiver.
-
Read more: The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal
Should a waiver be issued, there is no legal mechanism that can compel the transfer of certain types of know-how or trade secrets.
-
Read more: The Patent Trial and Appeal Board Returns to the Supreme Court The Patent Trial and Appeal Board Returns to the Supreme Court
How the Court decides United States v. Arthrex will have important implications for patent law and for administrative law more generally.
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported? Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported?
Are manufacturing method patents warranted intellectual property protections, or groundless obstacles to competition?
-
Read more: When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims
In this post, I explore several problematic aspects of the court’s reasoning for rejecting the claims of pay-for-delay and market allocation.
-
Read more: Year in Review: Biosimilars Year in Review: Biosimilars
In November 2020, the FDA released its most recent draft guidance for industry on biosimilarity and interchangeability
